{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:39:27Z","timestamp":1788503967959,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-934237"],"award-info":[{"award-number":["SLS-934237"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001725","name":"Royal Swedish Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.pan.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:35:16Z","timestamp":1765326916000},"page":"154-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3777-6887","authenticated-orcid":false,"given":"Oskar","family":"Franklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-4516","authenticated-orcid":false,"given":"Thomas F.","family":"Stoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Rodriguez Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-6094","authenticated-orcid":false,"given":"Toshitaka","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3359-4864","authenticated-orcid":false,"given":"Hiroyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-6330","authenticated-orcid":false,"given":"Kathryn","family":"Colborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-4105","authenticated-orcid":false,"given":"Ana","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pan.2025.12.007_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.pan.2025.12.007_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib3","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.pan.2025.12.007_bib4","first-page":"375","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.pan.2025.12.007_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2025.12.007_bib6","unstructured":"NCCN Clinical Practice Guidelines in oncology (NCCN guidelines\u00ae) pancreatic adenocarcinoma. Version 1.2022. Published online February 24, 2022."},{"issue":"20","key":"10.1016\/j.pan.2025.12.007_bib7","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1200\/JCO.2017.72.4948","article-title":"Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice guideline update","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib8","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1634\/theoncologist.2015-0316","article-title":"Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer","volume":"21","author":"Shaib","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","volume":"21","author":"Stoop","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"19","key":"10.1016\/j.pan.2025.12.007_bib11","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.pan.2025.12.007_bib12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.pan.2025.12.007_bib13","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pan.2025.12.007_bib14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10073","key":"10.1016\/j.pan.2025.12.007_bib15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2025.12.007_bib16","doi-asserted-by":"crossref","unstructured":"Tempero MA, Pelzer U, O'Reilly EM, et al. Adjuvant nab-Paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. Published online December 15, 2022:JCO2201134. doi:10.1200\/JCO.22.01134.","DOI":"10.1200\/JCO.22.01134"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib17","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1245\/s10434-023-13353-2","article-title":"FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review","volume":"30","author":"Eshmuminov","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2025.12.007_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejca.2021.02.023","article-title":"Nab-Paclitaxel\/Gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - a GISCAD phase II randomized trial","volume":"148","author":"Cascinu","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.pan.2025.12.007_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.pan.2025.12.007_bib20","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1245\/s10434-016-5707-0","article-title":"Analysis of predictors of resection and survival in locally advanced stage III pancreatic cancer: does the nature of chemotherapy regimen influence outcomes?","volume":"24","author":"Bednar","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.pan.2025.12.007_bib21","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/annonc\/mdx495","article-title":"Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma","volume":"28","author":"Reni","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.pan.2025.12.007_bib24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.pan.2025.12.007_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.pan.2025.12.007_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/SLA.0000000000003301","article-title":"Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience","volume":"273","author":"Rangelova","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2025.12.007_bib27","doi-asserted-by":"crossref","unstructured":"Walma MS, Brada LJ, Patuleia SIS, et al. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: a multicenter prospective cohort. Eur J Surg Oncol : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Published online November 26, 2020. doi:10.1016\/j.ejso.2020.11.137.","DOI":"10.1016\/j.ejso.2020.11.137"},{"issue":"12","key":"10.1016\/j.pan.2025.12.007_bib28","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41416-021-01341-w","article-title":"Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort","volume":"124","author":"Auclin","year":"2021","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.pan.2025.12.007_bib29","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1245\/s10434-020-09520-4","article-title":"Pancreatectomy with vascular resection after neoadjuvant FOLFIRINOX: who survives more than a year after surgery?","volume":"28","author":"Garnier","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","article-title":"Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.pan.2025.12.007_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000005666","article-title":"Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study","volume":"278","author":"Seelen","year":"2023","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.pan.2025.12.007_bib33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis","volume":"110","author":"Brown","year":"2022","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.pan.2025.12.007_bib34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jnci\/djac018","article-title":"FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the trans-atlantic pancreatic surgery consortium","volume":"114","author":"Janssen","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib35","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/MPA.0000000000000876","article-title":"Patterns of care for locally advanced pancreatic adenocarcinoma using the national cancer database","volume":"46","author":"Amini","year":"2017","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.adro.2018.10.006","article-title":"Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers","volume":"4","author":"David","year":"2019","journal-title":"Advances in Radiation Oncology"},{"issue":"4","key":"10.1016\/j.pan.2025.12.007_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.pan.2025.12.007_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II Study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.pan.2025.12.007_bib39","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.pan.2025.12.007_bib40","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pan.2025.12.007_bib41","doi-asserted-by":"crossref","unstructured":"Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. Published online July 14, 2022. doi:10.1001\/jamaoncol.2022.2319.","DOI":"10.1001\/jamaoncol.2022.2319"},{"issue":"16_suppl","key":"10.1016\/j.pan.2025.12.007_bib42","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Orthod"},{"issue":"17","key":"10.1016\/j.pan.2025.12.007_bib43","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib44","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.3390\/curroncol30070499","article-title":"Radiotherapy for locally advanced pancreatic Adenocarcinoma\u2014A critical review of randomised trials","volume":"30","author":"Ejlsmark","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.pan.2025.12.007_bib45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pan.2025.12.007_bib46","doi-asserted-by":"crossref","unstructured":"Stoop TF, Seelen LWF, van \u2019t Land FR, et al. Nationwide use and outcome of surgery for locally advanced pancreatic cancer following induction chemotherapy. Ann Surg Oncol. Published online December 17, 2023. doi:10.1245\/s10434-023-14650-6.","DOI":"10.1016\/j.hpb.2023.07.176"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib47","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/jhbp.1049","article-title":"New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of hepato-biliary-pancreatic Surgery (JSHBPS)","volume":"29","author":"Oba","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"9","key":"10.1016\/j.pan.2025.12.007_bib48","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.hpb.2019.01.012","article-title":"Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer","volume":"21","author":"Kato","year":"2019","journal-title":"HPB"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib49","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-22-3089","article-title":"Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma","volume":"29","author":"Ecker","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.pan.2025.12.007_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100552","article-title":"Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)","volume":"7","author":"Hartlapp","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.pan.2025.12.007_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.hpb.2019.06.012","article-title":"Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival","volume":"22","author":"Heger","year":"2020","journal-title":"HPB"},{"issue":"11","key":"10.1016\/j.pan.2025.12.007_bib52","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1007\/s00261-021-03198-2","article-title":"Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria","volume":"46","author":"Yang","year":"2021","journal-title":"Abdom Radiol"},{"issue":"4","key":"10.1016\/j.pan.2025.12.007_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2214\/AJR.21.26931","article-title":"Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR expert Panel narrative review","volume":"218","author":"Soloff","year":"2022","journal-title":"Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.pan.2025.12.007_bib54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/bjs\/znac363","article-title":"Pancreatectomy with resection and reconstruction of the superior mesenteric artery","volume":"110","author":"Boggi","year":"2023","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.pan.2025.12.007_bib55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/SLA.0000000000004054","article-title":"Arterial resection in pancreatic cancer surgery: effective after a learning curve","volume":"275","author":"Loos","year":"2022","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.pan.2025.12.007_bib56","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/SLA.0000000000003010","article-title":"Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes?: a single institution's experience with 118 patients","volume":"271","author":"Bachellier","year":"2020","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.pan.2025.12.007_bib57","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/SLA.0000000000003568","article-title":"Management of locally advanced pancreatic cancer: results of an International Survey of Current practice","volume":"273","author":"Reames","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2025.12.007_bib58","doi-asserted-by":"crossref","unstructured":"Oba A, Croce C, Hosokawa P, et al. Prognosis based definition of resectability in pancreatic cancer: a Road Map to New Guidelines. Ann Surg. Published online March 6, 2020. doi:10.1097\/SLA.0000000000003859.","DOI":"10.1097\/SLA.0000000000003859"},{"issue":"12","key":"10.1016\/j.pan.2025.12.007_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.3617","article-title":"International validation of the eighth edition of the American Joint Committee on cancer (AJCC) TNM staging System in patients with resected pancreatic cancer","volume":"153","author":"van Roessel","year":"2018","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.pan.2025.12.007_bib60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1245\/s10434-021-10663-1","article-title":"Anatomic criteria determine resectability in locally advanced pancreatic cancer","volume":"29","author":"Gemenetzis","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.pan.2025.12.007_bib61","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.3390\/cancers13112797","article-title":"Gemcitabine\/Nab-Paclitaxel versus FOLFIRINOX in locally advanced pancreatic cancer: a European multicenter Study","volume":"13","author":"Williet","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.pan.2025.12.007_bib62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pan.2025.12.007_bib63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.pan.2025.12.007_bib64","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41416-021-01649-7","article-title":"A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study","volume":"126","author":"Su","year":"2022","journal-title":"Br J Cancer"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439032500715X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439032500715X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:18:43Z","timestamp":1773933523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S142439032500715X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S142439032500715X"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2025.12.007","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}